/data/photo/2020/08/29/5f4a49be67d22.jpg)
[ad_1]
JAKARTA, KOMPAS.com – President Joko Widodo ordered his ministers to prepare a mass vaccination schedule for Covid-19 while the vaccine candidate is still in the third phase of clinical trials.
The instruction was relayed by Jokowi while presiding over a limited meeting on the management of Covid-19 and the virtual national economic recovery at the Merdeka Palace, Jakarta, on Monday (9/28/2020).
“I ask for the vaccination plan, the vaccine injection plan is planned in detail as soon as possible. I ask for detailed planning in the last two weeks,” Jokowi said during a virtual opening at Merdeka Palace, Jakarta, on Monday (28 / 9/2020).
Also read: 102 million people will be injected with the Covid-19 vaccine throughout 2021, who will they be?
He said planning should include the time of vaccination, the destination for vaccination and the groups that have priority to be vaccinated.
He called for all the planning to be detailed so that the government would then implement it once the clinical trial of the vaccine is completed.
“Everything must be well planned so that when the vaccine is available, it is just a matter of immediate implementation of implementation in the field,” Jokowi said.
Presidential regulation on vaccines
Jokowi will also issue a presidential regulation (perpres) as the legal basis for acquiring and administering the Covid-19 vaccine to the public.
This was transmitted by the president of the Policy Committee for the Management of Covid-19 and the National Economic Recovery, Airlangga Hartarto.
“Regarding the vaccination plan, where the vaccination plan is prepared. The government has produced a presidential regulation,” Airlangga said after a limited meeting with President Joko Widodo on Monday (9/28/2020).
The government has prepared a budget of 21.8 billion IDR for the Covid-19 vaccination process.
Also read: Jokowi prepares the presidential decree on the Covid-19 vaccine
The vaccination budget is divided in two. In 2020, the prepared budget is 3.8 trillion IDR. Meanwhile, in 2021, the prepared budget will reach Rs 18 trillion.
“There is a need for funds for vaccines that have been prepared this year in the amount of Rp. 3.8 billion and the 2021 State Budget for Rp. 18 billion,” said Airlangga.
“For the vaccination plan, the government has drawn up a Presidential Decree, then road map related to vaccination, “Airlangga said.
The government estimates that the Covid-19 corona virus vaccine can begin to be distributed and injected to the public from January 2021.
By the end of 2021, the government aims to get 102 million people vaccinated.
Based on these data, vaccination will be carried out in five stages.
The first phase will take place in January and will then continue with the next phase throughout 2021.
The government has also divided people who receive the vaccine into six groups.
The first group, the people who are at the forefront in the treatment of Covid-19, that is, 1.31 million people.
The second group are people who have close contact with Covid-19 patients. The target for this group has been set at 50,000 people.
Also read: PMK Coordinating Minister: Speakers and Teachers are Priority for Covid-19 Vaccine Recipients
Third, those responsible for public services with a goal of 715,000 people. For this group, the government will distribute the vaccine in four stages.
The fourth group, that is, the general public with a target of 92.28 million people. The distribution process will be carried out in five stages.
The next group, 4.36 million workers, whose distribution is divided into two stages.
At the time, the state civil service group (ASN) and the legislature were 3.72 million people.
In total, there are 102,451,500 people who will receive the vaccine throughout 2021.
Each person will receive two vaccinations 14 days apart.
This vaccine will be administered by doctors, nurses, and midwives in government, private health services, and educational institutions.
Additionally, vaccination can involve health authorities at the point of entry into the country.
Especially for people with congenital or comorbid diseases, the vaccines will be administered by a specialist.
Read Also: Government Says Sinovac Covid-19 Vaccine Clinical Trial Works Without Problems
Clinical trials are going well
Meanwhile, a member of the Covid-19 Vaccine Development Acceleration Team and Foreign Minister Retno Marsudi said that the third phase of the clinical trial of a candidate vaccine from a Chinese medical company, Sinovac, was proceeding smoothly. .
This was transmitted by Retno after a virtual meeting with President Joko Widodo, on Monday (9/28/2020).
“Based on communication with the clinical trial team, Professor Kusnadi and also his team, we held a meeting this morning and received information that the reports received so far are working smoothly,” Retno said.
“And there are no serious effects. So the point is that it can work without problems and so far the results are good,” Retno said.
He said that currently the government and Sinovac continue to monitor the preparation of PT Bio Farma as a candidate for the main producer of the Covid-19 vaccine.
Meanwhile, from September 20 to 24, a team from Sinovac visited PT Bio Farma’s factory in Bandung, West Java to review the readiness of the state medical company.
The Sinovac delegation specifically visited buildings 21 and 43 of the PT Bio Farma factory. Building 21 will be used to produce a candidate vaccine for Sinovac.
The plan is for Building 43 to be used as a site to produce CEPI (Coalition for Innovations in Epidemic Preparedness) vaccine candidates.
“As everyone knows, Bio Farma has a total vaccine production capacity that has increased from 100 million to 250 million (vaccine units),” Retno said.
As is known, Indonesia took two paths to obtain the Covid-19 vaccine.
In the short term, Indonesia is working with medical companies from China, Sinovac and G42 based in the United Arab Emirates.
Also read: TNI will mobilize all distribution materials for the Covid-19 vaccine
In vaccine development, G42 is working with a Chinese medical company, Sinopharm.
Sinovac’s vaccine is currently in a third-phase clinical trial in Bandung, West Java, while the G42 vaccine is currently in a third-phase clinical trial in the United Arab Emirates.
In addition, through Bio Farma, Indonesia will strengthen its position in building vaccine production networks in the world by cooperating with CEPI in vaccine production.
Meanwhile, to build national resilience, Indonesia is developing a red and white vaccine whose program is run by the Eijkman Institute for Molecular Biology.
At present, the red and white vaccine is only in the early stage of development and clinical trials have not yet been conducted.
